Table 1 Sociodemographic characteristics and tumor specific data
| Â | Radical prostatectomy | Radiotherapy | p-value1 | ||||
|---|---|---|---|---|---|---|---|
Non-nerve-sparing (reference) | Nerve-sparing | Total | Brachytherapy | Combined (External/brachytherapy) | External | Â | |
(n = 256) | (n = 127) | (n = 133) | (n = 44) | (n = 37) | (n = 52) | ||
Age [mean ± SD] | 64.2 ± 6.3 | 59.7 ± 6.1 | 66.5 ± 5.5 | 65.0 ± 6.0 | 66.8 ± 5.5 | 67.7 ± 4.8 | <0.001 |
Partnership [N (%)] | |||||||
 Not living with a partner | 14 (5.5) | 6 (4.7) | 10 (7.5) | 4 (9.1) | 3 (8.1) | 3 (5.8) | 0.586 |
 Married or having a spouse | 239 (93.4) | 120(94.5) | 121 (91.0) | 39 (88.6) | 33 (89.2) | 49 (94.2) | |
 Missing | 3 (1.2) | 1 (0.8) | 2 (1.5) | 1 (2.3) | 1 (2.7) | 0 (0.0) | |
Education [N (%)] | |||||||
 without | - | - | 2 (1.5) | 0 (0.0) | 0 (0.0) | 2 (3.8) | 0.113 |
 8-9 years | 127 (49.6) | 50 (39.4) | 65 (48.9) | 20 (45.5) | 21 (56.8) | 24 (46.2) | |
 10-11 years | 59 (23.0) | 31 (24.4) | 27 (20.3) | 11 (25.0) | 10 (27.0) | 6 (11.5) | |
 >=12 years | 70 (27.3) | 45 (35.4) | 38 (28.6) | 13 (29.5) | 6 (16.2) | 19 (36.5) | |
 Missing | - | 1 (0.8) | 1 (0.8) | 0 (0.0) | 0 (0.0) | 1 (1.9) | |
Employment status [N (%)] | |||||||
 Employed | 70 (27.3) | 67 (52.8) | 17 (12.8) | 9 (20.5) | 2 (5.4) | 6 (11.5) | <0.001 |
 Non employed | 180 (70.3) | 59 (46.5) | 114 (85.7) | 33 (75.0) | 35 (94.6) | 46 (88.5) | |
 Missing | 6 (2.3) | 1 (0.8) | 2 (1.5) | 2 (4.5) | 0 (0.0) | 0 (0.0) | |
Living area [N (%)] | |||||||
 Rural | 149 (58.3) | 85 (66.9) | 56 (42.1) | 29 (65.9) | 18 (48.6) | 9 (17.3) | <0.001 |
 Urban | 102 (39.8) | 40 (31.5) | 71 (53.4) | 12 (27.3) | 17 (45.9) | 42 (80.8) | |
 Missing | 5 (2.0) | 2 (1.6) | 6 (4.5) | 3 (6.8) | 2 (5.4) | 1 (1.9) | |
Pre-therapeutic Gleason score, [mean ± SD] | 6.6 ± 1.2 | 6.5 ± 1.0 | 6.0 ± 13.1 | 5.4 ± 1.4 | 6.1 ± 1.6 | 6.4 ± 1.1 | 0.110 |
 Missing [N] | 2 | 1 | 33 | 25 | 7 | 3 | |
Pre-therapeutic PSA score, [mean ± SD] | 11.4 ± 21.3 | 8.0 ± 4.7 | 13.7 ± 17.0 | 10.8 ± 15.0 | 17.6 ± 14.4 | 13.2 ± 19.9 | 0.032 |
 Missing [N] | 5 | 1 | 2 | 1 | 1 | - | |
Pre-baseline androgen deprivation therapy [N (%)] | |||||||
 Yes | 10 (3.9) | 1 (0.8) | 51 (38.3) | 20 (45.4) | 13 (35.1) | 18 (34.6) | <0.001 |
 No | 185 (72.2) | 81 (63.8) | 46 (34.6) | 16 (36.4) | 12 (32.4) | 19 (36.5) | |
 Missing | 61 (23.8) | 45 (35.4) | 36 (27.0) | 8 (18.2) | 12 (32.4) | 16 (30.8) | |
Tumour stage at diagnosis [N %)] | |||||||
 T1 | 2 (0.8) | - | 32 (24.0) | 1 (2.3) | 1 (2.7) | 29 (55.8) | <0.001 |
 T2 | 142 (55.5) | 103 (81.1) | 39 (29.3) | 8 (18.2) | 17 (45.9) | 14 (26.9) | |
 T3 | 105 (41.0) | 21 (16.5) | 20 (15.0) | 1 (2.3) | 12 (32.4) | 7 (13.5) | |
 Missing | 7 (2.7) | 3 (2.4) | 43 (32.3) | 34 (77.3) | 7 (18.9) | 2 (3.8) | |
Risk stratification [N (%)] | |||||||
 Low | 13 (5.1) | 7 (5.5) | 25 (18.8) | 6 (13.6) | 0 (0.0) | 19 (36.5) | <0.001 |
 Intermediate | 33 (12.9) | 15 (11.8) | 22 (16.5) | 2 (4.5) | 8 (21.6) | 12 (23.1) | |
 High | 205 (80.1) | 103 (81.1) | 47 (35.3) | 4 (9.1) | 25 (67.6) | 18 (34.6) | |
 Missing | 5 (1.9) | 2 (1.6) | 39 (29.3) | 32 (72.7) | 4 (10.8) | 3 (5.8) | |
Operation condition [N (%)] | |||||||
 Retropubic | 251 (98.0) | 124 (97.6) | n.a. | n.a. | n.a. | n.a. | n.a. |
 Perineal | 5 (2.0) | 2 (1.6) | |||||
 Missing | - | 1 (0.8) | |||||
Sexual functioning, [mean ± SD] | 41.5 ± 21.2 | 54.7 ± 16.5 | 33.1 ± 22.3 | 26.7 ± 22.1 | 32.4 ± 21.6 | 39.7 ± 21.7 | <0.001 |
 Missing [N] | 92 | 36 | 44 | 11 | 15 | 18 | |